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Beneficial impact of spironolactone in diabetic nephropathy.
Background. Aldosterone has been suggested to play a role
in the initiation and progression of diabetic nephropathy. Cur-
rently recommended treatment with angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II receptor block-
ers [renin-angiotensin system (RAS) blockade] does not sup-
press circulating aldosterone sufficiently. We therefore aimed to
evaluate the short-term effect of aldosterone antagonism with
spironolactone on albuminuria and blood pressure in diabetic
nephropathy.
Methods. Twenty Caucasian type 1 diabetic patients with
persistent macroalbuminuria despite antihypertensive treat-
ment, including RAS blockade, completed this double-masked,
randomized cross-over trial. Patients were treated in random
order with spironolactone 25 mg once daily and matched
placebo for two months, respectively, on top of usual antihy-
pertensive treatment. After each treatment period albuminuria,
24-hour blood pressure, and glomerular filtration rate (GFR)
were determined.
Results. Spironolactone on top of usual antihypertensive
treatment induced a 30% (95% CI 17 to 41) reduction in al-
buminuria from [geometric mean (95% CI)] 831 (624 to 1106)
mg/24-hour on placebo treatment (P < 0.001), and a reduction
in fractional albumin clearance of 35% (20 to 46, P < 0.001).
Twenty-four–hour blood pressure showed an insignificant re-
duction of [mean reduction (95% CI)] 8 (−1 to 17)/3 (−0.2
to 7) mm Hg (P < 0.10). There was an insignificant reversible
reduction in GFR during treatment with spironolactone. On
spironolactone treatment, one patient was excluded due to hy-
perkalemia (plasma potassium 5.7 mmol/L) and one due to or-
thostatic dizziness. Otherwise treatment was well tolerated.
Conclusion. Our results suggest that spironolactone treat-
ment on top of recommended antihypertensive treatment re-
duces blood pressure and may offer additional renoprotection
in type 1 diabetic patients with diabetic nephropathy.
Diabetic nephropathy has become the most com-
mon cause of end-stage renal disease (ESRD), despite
improved prognosis due to early aggressive antihy-
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pertensive treatment, including blockade of the renin-
angiotensin system (RAS) [1, 2]. Thus, there is an unmet
need for improved renoprotective treatment in patients
with diabetic nephropathy.
Angiotensin II (Ang II) has been considered the main
mediator of the RAS; recently, however, focus has turned
to aldosterone as an important additional factor in the
initiation and progression of diabetic nephropathy inde-
pendent of blood pressure [3]. In several experimental
studies, aldosterone has been shown to induce inflamma-
tion, endothelial dysfunction, glomerular sclerosis, and
tubular damage [4, 5].
Clinical trials with RAS blockade by angiotensin-
converting enzyme (ACE) inhibitors (ACEI) [6, 7] or
angiotensin II receptor antagonists (ARB) [8], or the
combination of both [9], has demonstrated that plasma
aldosterone levels may increase during treatment (i.e.,
the aldosterone escape phenomenon). In fact, it has been
reported that up to 20% of patients with chronic heart
failure have elevated plasma levels of aldosterone de-
spite long-term RAS blockade [7]. Data on aldosterone
escape in kidney disease are limited, but Sato et al [6]
found that plasma aldosterone levels increased in 40%
of type 2 diabetic patients with early nephropathy dur-
ing 40 weeks of ACEI therapy. Recently, we have shown
that aldosterone escape during long-term losartan treat-
ment occurs in 40% of type 1 diabetic patients with di-
abetic nephropathy and is associated with an enhanced
rate of decline in glomerular filtration rate (GFR) [8].
These data and data from animal studies [10] suggest that
aldosterone may play a role in the initiation and progres-
sion of kidney disease.
Therefore, we evaluated the safety and efficacy of
spironolactone in addition to conventional antihyperten-
sive treatment, in type 1 diabetic patients with persis-
tent albuminuria despite recommended antihypertensive
treatment, including ACEI or ARB.
METHODS
Subjects
From the Steno Diabetes Center, we consecutively en-
rolled 22 Caucasian type 1 diabetic patients with diabetic
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nephropathy (16 men and 6 women). Despite antihyper-
tensive treatment, including an ACEI or ARB in rec-
ommended dose, the patients had persistent albuminuria
(>300 mg/24-hour). Diabetic nephropathy was diagnosed
clinically if the following criteria were fulfilled: persistent
albuminuria, presence of diabetic retinopathy, and the
absence of any clinical or laboratory evidence of other
kidney or renal tract disease.
Exclusion criteria were GFR <30 mL · min−1 ·
1.73 m−2, plasma potassium >4.5 mmol/L, known renal
artery stenosis, age <18 years, pregnancy, breastfeeding,
lack of safe contraception in women, abuse of alcohol
or medicine, inability to understand the patient infor-
mation, allergy to ACEI, ARB, or spironolactone. The
prespecified exclusion criteria during the study were se-
vere symptoms of hypotension, systolic blood pressure
<100 mm Hg, increase in plasma creatinine of >35%
within the first two weeks of treatment, or plasma potas-
sium >5.5 mmol/L.
Based on data in our patient registry, 92 patients ful-
filled inclusion criteria for the present study and were
invited to participate in the study. Of these, 62 patients
declined and 30 patients agreed to participate. However,
eight patients were not suitable for inclusion: six because
of too low GFR, two because of psychiatric disorders. A
total of 22 patients were included in the study.
Design
We performed a randomized, double-masked, placebo-
controlled, crossover trial consisting of two treatment
periods, each lasting two months. In random order, pa-
tients received spironolactone 25 mg once daily for two
months and matching placebo tablets once daily for two
months. There was no drug washout period between
treatment periods (‘active washout’ [11]). The study med-
ication was given in the morning and was added to the
patients’ usual antihypertensive treatment, including a
RAS-blocking agent in recommended dose (see Results).
All patients, except for one, received diuretics in individ-
ual doses before entry into the study to treat and prevent
fluid retention and hyperkalemia. The type and dose of
prior antihypertensive treatment, including diuretics, re-
mained unchanged throughout the study.
At the end of each treatment period, the primary
end point, albuminuria, and the secondary end points,
24-hour blood pressure and GFR, were determined. On
the day of GFR determination, patients arrived in a fast-
ing state at 8:00 AM; after 30 minutes of supine rest the ini-
tial blood samples were drawn and breakfast was served.
For safety reasons, blood pressure, plasma potassium,
plasma sodium, and plasma creatinine were determined
1, 2, and 4 weeks after the beginning of each treatment
period.
Randomization was concealed with computer-
generated envelopes. The code was not broken until all
data were entered into a database that was locked for
editing.
Drug compliance was assessed by tablet counts. Di-
etary intake of protein and salt was not restricted; how-
ever, all patients were given written and oral information
on how to lower potassium intake in the diet.
The study was performed according to the principles of
the Declaration of Helsinki and approved by the ethical
committee of Copenhagen County. All patients gave their
informed consent.
Laboratory procedures
Albuminuria was determined as the geometric mean of
three consecutive 24-hour urine collections, completed
immediately before the end of each treatment period
(Turbidimetry, Hitachi 912 system; Roche Diagnostics,
Mannheim, Germany). From 24-hour urine samples,
sodium, potassium, creatinine, and urea excretion were
determined (Hitachi 912 system; Roche Diagnostics).
To eliminate changes in albuminuria caused by vari-
ation in plasma albumin and GFR, we determined the
fractional clearance of albumin (hAlb) as [urinary albumin
excretion]/([plasma albumin concentration]×[GFR]),
where urinary albumin excretion was measured in the
four-hour urine collection during GFR determination.
Blood pressure was measured by a 24-hour ambulatory
blood pressure (ABP) device (Takeda TM2421; A & D
Medical, Tokyo, Japan). Blood pressure was measured ev-
ery 15 minutes during the day (7:00 AM to 11:00 PM) and
every 30 minutes during the night (11:00 PM to 7:00 AM).
Values were averaged for each hour before calculating
day, night, and 24-hour blood pressures. Office blood
pressure was measured using an appropriate cuff with a
sphygmomanometer after at least 10 minutes rest in the
sitting position. Three readings, two minutes apart and
read to the nearest two mm Hg, were recorded and the
average value was used for calculation.
GFR was measured after a single intravenous injec-
tion of 3.7 MBq 51Cr-EDTA at 8:30 AM by determining
the radioactivity in venous blood samples taken 180, 200,
220, and 240 minutes after injection [12, 13]. The results
were standardized for 1.73 m2 body surface area using
the patient’s surface area at the start of the study. The
mean day-to-day coefficient of variation was 4% in our
laboratory.
From venous samples, hemoglobin concentration
(Sysmex SF3000; Sysmex Corporation, Kobe, Japan),
and plasma potassium, sodium, creatinine, and choles-
terol concentrations were determined (Hitachi 912 sys-
tem; Roche Diagnostics), and HbA1c was measured by
high-performance liquid chromatography (normal range
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4.1–6.4%; Tosoh automated glycohemoglobin analyzer;
Tosoh Bioscience, Minato, Japan). Blood samples for
plasma renin activity and aldosterone concentrations
were taken after 30 minutes of supine rest. Plasma renin
activity was measured by a method based on determin-
ing by radioimmunoassay the amount of angiotensin I
generated, as previously described [14]. Plasma aldos-
terone was measured using a commercially available
radioimmunoassay (Coat-a-Count; Diagnostic Products
Corporation, Los Angeles, CA, USA).
Statistical analysis
For power calculation, we previously calculated the SD
(log scale 0.1771) of the mean difference in urinary al-
bumin excretion rate in three consecutive 24-hour urine
samples collected twice within three months in 36 patients
with diabetic nephropathy. On the basis of these data, a
sample-size calculation showed a necessary minimum of
16 patients to detect a 25% change in urinary excretion
rate (a = 0.05, b = 0.80).
Normally distributed variables are expressed as
mean ± SD (Table 1) and mean ± SEM. Changes in vari-
ables between visits are expressed as means with 95% CI.
Albuminuria, plasma renin activity, plasma aldosterone,
and hAlb clearance were logarithmically transformed be-
fore statistical analysis owing to their skewed distribution
and are given as geometric means (95% CI). Changes in
these variables during treatment with spironolactone as
compared to placebo are expressed in percent. All com-
parisons of normally or log normally distributed param-
eters were performed with a paired Student t test. Data
were tested for a period effect and a treatment-period in-
teraction with a two-sample t test comparing the mean dif-
ference and the mean average, respectively, when patients
were grouped according to order of treatment period [15].
Linear regression analysis was used to analyze for cor-
relations between the relative change in albuminuria and
changes in arterial blood pressure, GFR, plasma aldos-
terone levels, and plasma renin activity.
P < 0.05 was considered significant (two-tailed test).
Data were evaluated using SPSS version 12.0 (SPSS,
Chicago, IL, USA).
RESULTS
Twenty-two Caucasian patients were randomized in
the trial; 20 patients completed the study (see below) and
were included in the statistical analysis. Baseline clini-
cal data as well as usual antihypertensive treatment on
20 patients completing the study are presented in Table 1.
Patients who refused to participate in the study did not
differ significantly from patients included in the study in
regards to clinical and demographic characteristics (age,
duration of diabetes, duration of diabetic nephropathy,
Table 1. Baseline clinical data and baseline antihypertensive
treatment in 20 type 1 diabetic patients with diabetic nephropathy
Age years 45 (7)
Gender male/female 15/5
Duration of diabetics years 33 (6)
Duration of DN years 14 (5)
Retinopathy none/background/proliferative 0/2/18
Total number of antihypertensive drug 1/2/3/4 1/8/5/6
RAS blocking agent:
Enalapril 40/20/15 mg 9/1/1
Ramipril 10 mg 1
Lisinopril 40 mg 1
Captopril 100 mg 1
Losartan 100 mg 6
Patients receiving diuretics thiszide/furosemide 7/12
Patients receiving dihydropyridines 11
Patients receiving statins 13
DN, diabetic nephropathy. Data are given as N or mean (SD).
albuminuria, office blood pressure, and GFR, data not
shown).
During treatment with spironolactone in addition to
conventional antihypertensive treatment, albuminuria
was significantly reduced by 30% (95% CI 17 to 41)
compared to placebo treatment (P < 0.001) (Table 2).
The reduction in albuminuria was demonstrated in 17 of
the 20 patients (Fig. 1). There was a statistically insignif-
icant trend toward a decline in GFR of 3.4 (−0.1 to 6.9)
mL·min−1·1.73 m−2 and an increase in plasma creatinine
of 5 (−1 to 11) lmol·l−1. The fractional clearance of al-
bumin (halb) was reduced by 35% (20 to 46) (Table 2).
Overall, there was a trend toward a reduction in
24-hour ABP of 8 (−1 to 17) mm Hg systolic and 3 (−0.2
to 7) mm Hg diastolic during spironolactone treatment
as compared to placebo treatment (P < 0.10) (Table 2).
There was a significant reduction in day ABP of 10 (2 to
18) mm Hg systolic and 5 (1 to 8) mm Hg diastolic (P <
0.02) (Table 2), whereas night ABP remained unchanged
during spironolactone treatment. The mean reduction in
systolic blood pressure from day to night was 13% (SEM
3) during placebo treatment, and 8% (3) during spirono-
lactone treatment (P = 0.11). “Dipping” as defined by an
average reduction in systolic and diastolic ABP of ≥10%
from day to night was present in nine patients during
placebo treatment and seven patients during spironolac-
tone treatment.
Plasma aldosterone levels increased by 54% (18 to 101)
on spironolactone treatment compared to placebo treat-
ment, whereas plasma renin activity tended to increase
by 38% (−8 to 107) during spironolactone treatment.
Plasma as well as urinary levels of potassium and sodium
were similar in the two treatment periods (Table 2).
Using linear regression analysis, we found no correla-
tion between changes in albuminuria upon spironolac-
tone treatment and baseline variables (placebo period)
including age, BMI, ABP, total cholesterol, plasma
potassium, plasma renin activity, or salt intake. Baseline
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Table 2. Effect of adding spironolactone 25 mg to conventional antihypertensive medication, including an ACEI or ARB in recommended doses,
on kidney function, blood pressure, and laboratory variables in 20 type 1 diabetic patients with diabetic nephropathy
Placebo Spironolactone 25 mg Mean difference (95% CI) P value
Albuminuria mg/24-houra 831 (624 to 1106) 584 (441 to 829) −30% (−41 to −17) <0.001
Systolic blood pressure mm Hg
Office 136 (3) 131 (4) −6 (−14 to 2) 0.157
24-hour 144 (3) 136 (4) −8 (−17 to 1) 0.082
Day (7–23) 150 (3) 139 (4) −10 (−18 to −2) 0.017
Night (23–7) 131 (5) 130 (7) −1 (−14 to 12) 0.874
Diastolic blood pressure mm Hg
Office 72 (2) 71 (2) −1 (−5 to 2) 0.445
24-hour 72 (2) 69 (2) −3 (−7 to 0.2) 0.067
Day (7–23) 76 (2) 71 (2) −5 (−8 to −1) 0.010
Night (23–7) 65 (2) 64 (2) 0 (−5 to 5) 0.909
Glomerular filtration rate mL/min per 1.73 m2 85 (6) 81 (6) −3.4 (−6.9 to 0.1) 0.059
Fractional albumin clearance (halb) (× 10 −6)a 197 (122 to 317) 129 (78 to 210) −35% (−46 to −20) <0.001
Urinary sodium excretion mmol/24-hour 188 (13) 203 (13) 14 (−15 to 44) 0.306
Urinary K/Na-ratio 0.45 (0.05) 0.41 (0.03) −0.04 (−0.1 to 0.02) 0.192
Plasma renin activity ngAI/mL/ha 15 (10 to 21) 21 (13 to 33) 38% (−8 to 107) 0.110
Plasma aldosterone pg/mLa 44 (31 to 62) 68 (50 to 92) 54% (18 to 101) 0.003
Plasma creatinine lmol/L 115 (9) 120 (11) 5 (−1 to 11) 0.095
Plasma potassium mmol/L 4.0 (0.1) 4.2 (0.1) 0.13 (−0.04 to 0.3) 0.134
Plasma sodium mmol/L 138 (1) 136 (1) −1 (−3 to 1) 0.343
Hemoglobin mmol/L 7.9 (0.2) 7.7 (0.2) −0.18 (−0.4 to 0.3) 0.097
Hemoglobin A1c % 8.4 (0.2) 8.6 (0.2) 0.2 (−0.01 to 0.4) 0.056
Plasma cholesterol mmol/L 4.6 (0.2) 4.6 (0.2) 0.0 (−0.2 to 0.2) 0.936
Plasma low-density lipoprotein mmol/L 2.4 (0.1) 2.3 (0.2) −0.1 (−0.6 to 0.4) 0.121
Plasma high-density lipoprotein mmol/L 1.7 (0.2) 1.6 (0.1) −0.1 (−0.24 to 0.03) 0.660
AI, angiotension I.
Data are presented as mean (SEM).
aGeometric mean (95% CI).
albuminuria was not significantly correlated to changes in
albuminuria (r = 0.13, P = 0.59) (i.e., there was no order
effect). There was no significant correlation between al-
dosterone levels at baseline and changes in albuminuria
(r = −0.31, P = 0.19). Changes in plasma aldosterone
did not correlate significantly to changes in albumin-
uria (r = −0.24, P = 0.32); however, changes in plasma
renin activity correlated to relative changes in albumin-
uria (r = −0.48, P = 0.03) (i.e., an increase in plasma
renin activity corresponded to a more pronounced re-
duction in albuminuria) (Fig. 2). Furthermore, changes in
GFR correlated to changes in albuminuria (i.e., a decline
in GFR was associated with a decrease in albuminuria)
(Fig. 3). Changes in albuminuria were neither correlated
to changes in systolic or diastolic 24-hour ABP (r <0.17,
P ≥ 0.5), nor to changes in systolic or diastolic day ABP
(r <0.20, P ≥ 0.4) in univariate analyses. Similarly, the
effect of spironolactone treatment on albuminuria was
unchanged after adjustment for the treatment effect on
blood pressure.
The statistical analysis revealed no evidence of a pe-
riod effect or a treatment-period interaction on albumin-
uria, 24-hour ABP, GFR, plasma renin activity, or plasma
aldosterone.
Throughout the study, all patients received RAS block-
ing treatment in recommended doses (Table 1); doses re-
mained unchanged during the study. The median number
of antihypertensive drugs in addition to the study med-
ication was 3 (range 1–4). Compliance as assessed by
tablet count was 98% (68–100). One patient took less
than the required 80% of the study medication (68%) in
the spironolactone treatment period; however, this was
not due to adverse effects of the study medication.
Adverse effects
Of 22 patients included, two patients were excluded
during active treatment with spironolactone, one due to
hyperkalemia (plasma potassium 5.7 mmol/L) after four
weeks treatment, and one due to severe symptoms of
orthostatic hypotension. Slightly elevated potassium lev-
els occurred in further two patients, of whom one was
treated with kayexalate (sodium polystyrene sulfonate)
in both treatment periods due to slight-to-moderate
hyperkalemia (plasma potassium 5.0–5.4 mmol/L), and
one patient who had two measurements of potassium
>5.0 mmol/L during spironolactone treatment, which was
reversed by low potassium diet. One patient had a re-
versible increase in plasma creatinine of 33% after two
months’ spironolactone treatment. Furthermore, there
was an insignificant decrease in hemoglobin and an in-
crease in HbA1c (NS, Table 2). No patients reported gy-
necomastia or other anti-androgenic induced untoward
effects of spironolactone.
DISCUSSION
In our double-masked, randomized crossover study,
spironolactone on top of conventional antihypertensive
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Fig. 1. Individual responses to spironolactone 25 mg once daily for two
months added to recommended antihypertensive treatment in 20 type
1 diabetic patients with diabetic nephropathy. Overall reduction was
30%, P < 0.001.
treatment, including RAS blockade, induced a mean re-
duction in albuminuria of 30% in type 1 diabetic patients
with diabetic nephropathy. The treatment induced a ten-
dency to a lower 24-hour ABP and GFR. The fractional
clearance of albumin was significantly reduced by 35%.
Results from recent open-labeled studies suggest a
beneficial effect of aldosterone antagonism in various
nephropathies, including type 2 diabetic patients with
macro- and microalbuminuria [6, 16, 17]. Our study is
the first one to demonstrate an additional antihyperten-
sive and albuminuria lowering effect of spironolactone
in type 1 diabetic patients with persistent macroalbumin-
uria despite recommended antihypertensive treatment,
including RAS blockade.
Albuminuria and blood pressure are strong predictors
of poor renal and cardiovascular outcome in diabetic
patients. Large clinical trials have demonstrated that a
reduction in these risk factors by aggressive antihyperten-
sive treatment translates into markedly improved renal
[18–20] and cardiovascular [21, 22] outcome. Short-term
reductions in albuminuria are a strong predictor of the
long-term outcome (i.e., Atkins et al [20] reported that
for each halving of proteinuria level during the first year
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Fig. 2. Linear regression analysis between the changes in plasma
renin activity and changes in albuminuria in type 1 diabetic patients
with diabetic nephropathy treated with spironolactone 25 mg daily
(r = −0.48, P = 0.03).
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Fig. 3. Linear regression analysis between the changes in GFR
and changes in albuminuria in type 1 diabetic patients with
diabetic nephropathy treated with spironolactone 25 mg daily
(r = 0.49, P = 0.03).
of treatment, the risk for kidney failure was reduced by
more than half during follow up in the IDNT study pop-
ulation). Furthermore, de Zeeuw et al [19] found that
every 50% reduction in albuminuria in the first 6 months
of treatment was associated with a reduction in risk of
45% for ESRD and 27% for the heart failure end point
during later follow-up [21]. These findings suggest that
the reduction in albuminuria and blood pressure upon
spironolactone treatment as demonstrated in our study is
renoprotective. However, the long-term effect of aldos-
terone antagonism on blood pressure, albuminuria and,
more importantly, decline in GFR, doubling of plasma
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creatinine, ESRD, and death needs to be evaluated in
patients with diabetic nephropathy.
Several mechanisms may be involved in the antipro-
teinuric effect of spironolactone (i.e., changes in the
size and charge selective properties of the glomerular
vascular barrier, reduced glomerular capillary hydraulic
pressure, and increased tubular protein reabsorption)
[23–25]. Changes in tubular protein reabsorption can
probably be excluded since the process should already
operate at maximum speed in overt nephropathy. Our
data contain no relevant information with regard to al-
terations in the size and charge selective properties of
the glomerular capillary wall. However, it has been sug-
gested that RAS blockade (ACEI/ARB) in incipient and
overt diabetic nephropathy in man can reduce the size se-
lective abnormalities of the glomerular barrier [26] and
normalize estimated glomerular pressure [27]. The re-
duction in albuminuria in our study was associated with
the reversible decline in GFR, which may suggest that
spironolactone induces a reduction in the intraglomerular
hydraulic pressure. This suggestion is supported by exper-
imental studies [28]. Furthermore, it is well established
that autoregulation of GFR (and renal plasma flow) is
impaired/abolished in human diabetic nephropathy [29,
30], which enhance the downstream transmission of the
observed blood pressure reduction in our study. Even
though we did not find a statistically significant correla-
tion between reduction in 24-hour blood pressure and
albuminuria, other data suggest that the observed blood
pressure reduction might contribute to diminished albu-
minuria [31]. Epstein et al reported preliminary data from
a double-masked parallel study, comparing the effect of
enalapril monotherapy, eplerenone (a new selective al-
dosterone receptor antagonist) monotherapy, or a com-
bination of both in type 2 diabetic patients with mild to
moderate hypertension and microalbuminuria [abstract;
Epstein M et al. Am J Hypertens 15(Suppl 1):A24, 2002].
After 24 weeks of treatment, eplerenone was more effec-
tive (62%) in reducing albuminuria than enalapril (45%),
and the combination was even more effective (74%) than
either monotherapy, despite similar reductions in systolic
and diastolic blood pressure in all groups.
In an open-labeled study, Sato et al [6] added spirono-
lactone 25 mg to ACEI treatment in 13 type 2 diabetic
patients with early nephropathy who had developed al-
dosterone escape during 40 weeks of ACEI therapy. Af-
ter 24 weeks with combination treatment, they found a
further significant reduction in albuminuria compared to
ACEI monotherapy. Patients who did not develop aldos-
terone escape (N = 27) were not treated with spirono-
lactone. In our study, presence or absence of aldosterone
escape could not be determined since patients were on
long-term (years) stable RAS blockade. However, we
found that 17 of 20 patients completing the study had
a reduction in albuminuria during spironolactone treat-
ment, suggesting that the albuminuria-reducing effect is
not confined to patients with aldosterone escape, which
has been reported to occur in up to 40% of patients on
ACEI or ARB [6–8].
The rationale of blocking the aldosterone receptor on
top of RAS blockade is the finding that aldosterone lev-
els have been reported to increase (i.e., aldosterone es-
cape) during RAS blockade in several studies [6–8]. In
experimental studies, it has been shown that circulating
aldosterone per se has a nephrotoxic effect by induc-
ing vascular and glomerular sclerosis, inflammation, and
tubular damage independently of angiotensin II (Ang II)
[3, 10, 32–34]. Hemodynamic and nonhemodynamic ac-
tions of aldosterone have been suggested to contribute
the progressive renal injury [10]. These actions are medi-
ated either through classic genomic mechanisms via the
intracellular mineralocorticoid receptor or through fast
nongenomic actions characterized by rapid onset, and in-
sensitivity to spironolactone and agents inhibiting tran-
scription and protein synthesis (i.e., aldosterone has been
shown to induce a fast nongenomic vasoconstriction [35,
36]), as well as having a slower genomic hemodynamic
action, including up-regulation of Ang II receptors [37,
38], increased vasoconstrictive effects of catecholamines
[39], and impaired acetylcholine-induced vasodilatation
[40]. The nonhemodynamic effects of aldosterone have
been suggested to include up-regulation of the proscle-
rotic growth factors PAI-1 and TGF-b1, as well as pro-
motion of macrophage infiltration, consequently leading
to renal fibrosis [41].
Dual blockade of the RAS with an ACEI and an
ARB in diabetic nephropathy has been shown to re-
duce albuminuria and blood pressure in the same order
of magnitude as found in the present study [42–45].
The mechanism behind the beneficial effect of dual
RAS blockade is poorly understood; however, in a com-
bined analysis of 51 type 1 diabetic patients with di-
abetic nephropathy, dual blockade induced a reduc-
tion in plasma aldosterone levels of 28% compared to
ACEI monotherapy [Schjoedt K et al, Horm Metab Res
37(Suppl 1):4–8, 2005]. The decrease in plasma aldos-
terone was associated with the reduction in albuminuria
in a multivariate linear regression analysis, suggesting
that part of the effect of dual RAS blockade can be ex-
plained by indirect aldosterone blockade. Whether a fur-
ther renoprotective effect could be obtained by adding
spironolactone to dual RAS blockade (i.e., “triple block-
ade”) could be the next target for investigation.
There was a tendency toward an increase in HbA1c dur-
ing spironolactone treatment in our study. Davies et al
[46] recently reported a similar increase in HbA1c dur-
ing spironolactone treatment in 42 type 2 diabetic pa-
tients without diabetic nephropathy. They found that this
increase correlated significantly with a worsening in en-
dothelial dysfunction, as determined by the response in
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forearm blood flow to acetylcholine. It is noteworthy that
half of their patients examined had no diabetic compli-
cations, and half of the patients met the entry criteria for
the diabetic subpopulation in the HOPE study [47] (i.e.,
a previous cardiovascular event or another cardiovascu-
lar risk factor), but not dipstick-positive proteinuria. The
patients, therefore, did not have the same potential bene-
ficial effect of spironolactone as our patients with diabetic
nephropathy. Whether endothelial function is worsened
upon spironolactone treatment in diabetic patients with
diabetic nephropathy has not been determined.
Prior to the Randomized Aldactone Evaluation Study
(RALES) [48], the RALES Investigators performed a
dose-finding study [49] in 214 patients with symptomatic
heart failure, comparing effect and side effects of spirono-
lactone 12.5, 25, 50, and 75 mg daily to placebo. They
found a dose-dependent risk of hyperkalemia and con-
cluded that the initial dose of spironolactone should not
exceed 25 mg × 1 daily. Patients with type 1 diabetes
and serum creatinine >180 lmol · l−1 were excluded. In
our patients with diabetic nephropathy and normal or
slight-to-moderately reduced kidney function, one has to
be even more cautious in order to avoid hyperkalemia.
We therefore measured plasma potassium after 1, 2, and
4 weeks of treatment, and found that hyperkalemia could
occur at any of these times. To reduce the risk of hyper-
kalemia, patients should be treated with a loop diuretic
and most patients need to have their potassium supple-
ment withdrawn and, furthermore, to be educated in a
potassium sparing diet. With this regimen, spironolactone
treatment was generally well tolerated in our study; with-
drawal of spironolactone due to hyperkalemia was only
necessary in one of 22 type 1 diabetic patients with dia-
betic nephropathy and GFR >30 mL · min−1 · 1.73 m−2.
One patient had transiently elevated plasma potassium,
which was controlled by dietary advice, and kayexalate
(sodium polystyrene sulfonate) was prescribed to one
patient in both treatment periods. In addition, three pa-
tients, of whom one was excluded, experienced symptoms
of orthostatic hypotension during spironolactone treat-
ment. No patients experienced gynecomastia or other
antiandrogenic side effects during the study, but the ex-
posure time was only two months.
In our study there was a significant reduction in day
ABP, whereas night ABP remained unchanged during
spironolactone treatment. This may suggest that spirono-
lactone should be administered twice daily in order to
obtain the beneficial nocturnal dip in ABP.
CONCLUSION
Our short-term study suggests that spironolactone
25 mg daily in addition to recommended antihypertensive
treatment, including ACEIs or ARBs, is well tolerated,
and may offer beneficial renoprotective effect in type 1
diabetic patients with diabetic nephropathy. Future tri-
als are needed to evaluate the long-term renoprotective
effect and tolerability of spironolactone and newer aldos-
terone antagonists in patients with diabetic nephropathy.
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